



Radius Health, Inc.  
Investor Relations Department  
950 Winter St, North Building 1st Floor  
North Building 1st Floor  
Waltham, MA 02451  
United States

[Visit IR website](#)  
[Sign-up for Email alerts](#)

#### NASDAQ: RDUS

Last Trade:	32.61
Trade Time:	4:00 PM ET Apr 24, 2018
Change:	-0.41 <span style="color: red;">▼</span> (-1.242%)
Day Range	32.06 - 33.82
52-Week Range	24.66 - 49.16
Volume	507,328

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Radius' lead product, TYMLOS (abaloparatide) Injection was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. Radius' Marketing Authorisation Application (MAA) for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis is under regulatory review in Europe. The Radius c... [\(more\)](#)

## Stock Performance



### Press Releases [\[ View all \]](#)

- Apr 24, 2018*  
[Radius Health to Announce First Quarter 2018 Financial Results, Host Conference Call and Live Webcast on May 10, 2018](#)
- Mar 30, 2018*  
[Radius Health Initiates Phase 3 Clinical Trial of Abaloparatide Injection for the Treatment of Male Osteoporosis](#)
- Mar 22, 2018*  
[Radius Health Provides Update on CHMP Opinion for Abaloparatide-SC](#)
- Mar 17, 2018*  
[Radius Health Presents Positive Data for the ACTIVEExtend BMD Responder Analysis for TYMLOS™ \(abaloparatide\) Injection at ENDO 2018 Annual Meeting](#)
- Mar 12, 2018*  
[Radius Health to Present at ENDO 2018 Including Results of the ACTIVEExtend BMD Responder Analysis for TYMLOS™ \(abaloparatide\) Injection](#)

### Upcoming Events [\[ View all \]](#)

- May 10, 2018 8:00 AM ET*  
[Q1 Radius Health Inc Earnings Conference Call](#)
- Financials** [\[ View all \]](#)
  - [Fourth Quarter Financial Results](#)
- Mar 1, 2018*  
[Annual Report \(10-K\)](#)
- Apr 20, 2018*  
[Proxy Statement \(DEF 14A\)](#)
- Nov 2, 2017*  
[Quarterly Report \(10-Q\)](#)
- Aug 4, 2017*  
[Quarterly Report \(10-Q\)](#)
- May 2, 2017*  
[Quarterly Report \(10-Q\)](#)